### SESSION 4:RESEARCH PREPAREDNESS FOR HEALTH EMERGENCIES

What Should NPHIs do now to be Prepared to Rapidly Generate Knowledge when the next Emergency Occurs?

Moderated by Dr. Tyra Grove Krause, Executive Vice-President and Head of the Division of Epidemiological Infectious Disease Preparedness, Statens Serum Institut (SSI), Denmark



Dr. Tyra Grove Krause, Executive Vice-President and Head of the Division of Epidemiological Infectious Disease Preparedness, Statens Serum Institut (SSI), Denmark

# INTRODUCTORY SPEECH



Dr. Bjørn G. Iversen. Senior Medical Officer, Norwegian Institute of Public Health (FHI), Norway

# HOW THE EU IS BUILDING RESEARCH PREPAREDNESS TO BE BETTER PREPARED FOR THE NEXT PANDEMIC



# Agenda

- Experiences from the Covid-19 pandemc
- Directorate-Generals
  - o Sante, RTD, HERA
- Some main research initiatives
  - Be Ready
  - CoMeCT
  - EU Pandemic Preparedness Partnership



European Commission



## We were not prepared

We lacked

- Coordinated and interoperable plans
- Awareness in politics and society
- Healthcare systems ability to detect, prevent, manage and respond
- Medical countermeasures (drugs, tests, vaccines, equipment (PPE))
- Research
  - Fragmented infrastructure
  - Surge capacity plans





Directorate-General for Health and Food Safety (DG SANTE)





#### **Research & Innovation**

#### Executive Agencies

- ERCEA
- REA

# Funding programmesHorizon Europe




EUROPEAN MEDICINES AGENCY Science medicines health



### Organ-o-gram







## Timeline for various projects

	2	023							2024											025											202	6					
	10	11	12	1	2	3	4	5	6	7	89	10	11	12	1	2	3	4	5	6 7	78	9	10	11	12	1	2	3	4	5	6	7	8	9	10	11	12
CSA Be ready								Ju	ne 2022	2 - Ma	iy 2025																										
CoMeCT																	1.	12.202	3 - 1.1	2.202	6																
TCB Recover -> Aug 2023 Vaccelerate -> Jan 2024 (extension possible) Ecraid-Prime -> Nov 2024 EU Response -> Jun 2025 MPX Response -> Sept 2025											riable w ending																										
HORIZON-HLTH-2024-DISEASE-08-12	Prepa	re prop	osal	27.10.	23 - 1	1.4.20	024		Eva	luatio	n & con	tract									Poter	tial pe	riod f	or CS4	•												
HORIZON-HLTH-2024-DISEASE-17-01					P	ropos	al 16.	5. <mark>20</mark> 24										Pote	ential p	eriod	for CS	A															
HORIZON-HLTH-2024-DISEASE-XXX European Partnership for Pandemic Preparedness (co-funded)							Prep	are pro	opo sal :	11.04.	24 - 26.:	11.202	24	Ev	valuati	ion &	contra	ct				Pot	ential	start (	of the	Europe	eanel	Partner	rship o	on Pano	demic	c Prepa	aredne	ess			







- TOPIC: "HORIZON-HLTH-2021-DISEASE-04-06: Building a European partnership for pandemic preparedness"
- Budget: 2 Million Euros •
- Instrument: Coordination and Support Action (CSA) •
- 25 Partners from 13 European countries and 2 Associated • countries (Norway, UK)
- General coordination by ANRS | Maladies infectieuses • émérgentes







The SRIA main articulation is:

- The main articulation is around:
  - Prepare and understand
  - Prevent and anticipate
  - Respond and control
- 2 time frames:

Funded by the European Union

- Basic science and applied research in between epidemics: prepare a response to future crises, and to analyse the determining factors of the development and spread of emerging events.
- Response during the acute crisis phase;
- Research Areas: cover all the research domains already identified as crucial for a good response to pandemic/epidemic crises. They will include detection, diagnosis, prophylaxis, therapeutic, public health and societal domains
- First priority: Clinical research






# CoMeCT- Coordination Mechanism for Cohorts and Trials

- HORIZON-HLTH-2023-DISEASE-03-05: Pandemic preparedness and response: Sustaining established coordination mechanisms for European adaptive platform trials and/or for cohorts
- The purpose of CoMeCT is to enhance Europe's clinical research preparedness and response capacity to infectious disease outbreaks with epidemic potential through sustained strategic and scientific coordination of adaptive platform trials and cohort studies.
  - Promote timely deliverance of strong clinical evidence in support of patient- and population level interventions in epidemic/pandemic settings
  - Be ready to pivot to (re-)emerging infectious disease outbreak clinical research response efforts when needed, thereby being strategic assets for European clinical research preparedness and response
  - May provide valuable support for strained health systems in search of harmonized and pragmatic approaches to optimal patient care and public health measures.


















## Timeline for various projects

	2	023							2024											025											202	6					
	10	11	12	1	2	3	4	5	6	7	89	10	11	12	1	2	3	4	5	6 7	78	9	10	11	12	1	2	3	4	5	6	7	8	9	10	11	12
CSA Be ready								Ju	ne 2022	2 - Ma	iy 2025																										
CoMeCT																	1.	12.202	3 - 1.1	2.202	6																
TCB Recover -> Aug 2023 Vaccelerate -> Jan 2024 (extension possible) Ecraid-Prime -> Nov 2024 EU Response -> Jun 2025 MPX Response -> Sept 2025											riable w ending																										
HORIZON-HLTH-2024-DISEASE-08-12	Prepa	re prop	osal	27.10.	23 - 1	1.4.20	024		Eva	luatio	n & con	tract									Poter	tial pe	riod f	or CS4	•												
HORIZON-HLTH-2024-DISEASE-17-01					P	ropos	al 16.	5. <mark>20</mark> 24										Pote	ential p	eriod	for CS	A															
HORIZON-HLTH-2024-DISEASE-XXX European Partnership for Pandemic Preparedness (co-funded)							Prep	are pro	opo sal :	11.04.	24 - 26.:	11.202	24	Ev	valuati	ion &	contra	ct				Pot	ential	start (	of the	Europe	eanel	Partner	rship o	on Pano	demic	c Prepa	aredne	ess			



# EU Pandemic Preparedness Partnership

### HORIZON-HLTH-2024-DISEASE-08-12

- "Be Ready Plus"
- Call 27.11.2023 11.04.2024

### HORIZON-HLTH-2024-DISEASE-17-01

• Revised version of "Be Ready Plus"

### HORIZON-HLTH-2024-DISEASE-XX-XX

- European Partnership for Pandemic Preparedness
- "Ever-warm clinical trial networks for pandemic preparedness"
- EU budget: 100-300 million € + Co-funded by MS ??
- Buzz words: Collaboration, coordination, networks, breaking silos etc.


### **BE WP2 - PANDEMIC PREPAREDNESS READY PARTNERSHIP PROPOSAL**

- Type of Partnership (tbc by the Health Programme Committee of Horizon Europe) : Co-funded partnership
- Targeted budget: 200 300 M Euros
- In kind and in cash contributions of Member States.
   Depending on EU Member States financial commitments
- Duration: 7-10 years
- Beginning: expected mid 2025





### READY - PANDEMIC PREPAREDNESS PARTNERSHIP PROPOSAL GOVERNANCE









Dr. Jean-Claude Desenclos, Scientific Advisor, Santé publique France (SpF), France, and Senior Executive Board Advisor for IANPHI BUILDING BRIDGES TO RESILIENCE: IDENTIFYING INTERNATIONAL GOOD-PRACTICE PRINCIPLES IN APPLYING HEALTH PROMOTION TO EMERGENCY PREPAREDNESS AND RESPONSE


An IANPHI Project funded by the International Health Grant Programme of Canada (Grant number: 2324-HQ-000241)




## The IANPHI Stockholm Statement, December 2022

"National Public Health Institutes bring critical support at country level in the response to crises affecting health"

"National Public Health Institutes prioritize health equity and commit, through an appropriate investment in prevention and health promotion, towards healthier, and resilient populations".







## Context – Public Health Agency of Canada (PHAC) initiative

- Publication of Canada's Chief Public Health Officer report "Creating the Conditions for Resilient Communities: A Public Health Approach to Emergencies", December 2023
- Highlights the importance of determinants of health, their impacts and outcomes
- Provides opportunities to move forward, including specifically "Applying Health Promotion Actions to the Emergency Management Continuum"
- PHAC suggested IANPHI **to submit a project for funding** to the Canada International Health Grants Program (IHGP)



Project objectives and outcome:

#### Project objectives

- Collect review and analyze practice-based evidence in applying health promotion within EPR, particularly for COVID-19
- Identify good-practice principles taking into account the diversity of context and levels of their implementation
- Promote actively the principles of good practices identified
- Advocate for good practices to promote health promotion within EPR

#### Project outcome

 Increase IANPHI and NPHI members capacity to advocate collectively for health promotion interventions within its membership and in its strategy



Scoping review:

- Articles/reports on health promotion applied/implemented during emergency responses
- Full breadth of the emergency management continuum : prevention, mitigation, preparedness, community involvement, response, recovery...
- Will help **frame and refine** the search, collection, and analysis of **case studies**

### Four activities:

Survey, interviews and face-to-face meetings:

- Identify about 15 case studies among ANPHI members and partners in all 4 IANPHI regions
- Challenges, levers and successes to implement health promotion within EPR
- Identify specific practices: : building workforce, interaction between EPR and health promotion, strengthening community action and equity of response toward vulnerable communities...



Analysis of findings and identification of principles for good practice:

- Framework proposed by Eileen Ng and Pierpaolo de Colombani to identify best practices
- Good practice defined as "an intervention that has shown evidence of effectiveness in a particular setting and is likely to be replicable to other situations".
- 8 criteria: relevance, community participation, stakeholder collaboration, ethical soundness, replicability, effectiveness, efficiency and sustainability

Publications, communications & Dissemination:

- Best practices to promote through IANPHI network, WHO...
- Case studies, report, educational material, scientific articles

### Four activities:



Implementation:

- Activity 1:WHO Collaborating Centre for Health Promotion Research (HPRC)
- Activity 2 & 3: a Scientific Coordinator and a Project Assistant for interviews
- NPHI(s) that will receive funding for the 2 positions

#### Governance:

- Steering Committee (SC) to advise on the protocol & work plan
- Transparent process for the selection of NPHIs to carry out activities 2 & 3
- Chaired by an Executive Board (EB) advisor
- Reflect the **whole IANPHI membership**, include an additional EB advisor, members from the four regional networks & **experts from external organizations**
- Meet at least quarterly to monitor the implementation of the project

#### Partners:

- WHO's Health Systems Resilience( HSR) and Essential Public Health Function (EPHF) and Health Promotion Directorates
- Regional CDCs: <u>CARPHA</u>, <u>Africa CDC</u>, <u>ECDC</u>, <u>Gulf CDC</u>
- WHO Collaborative Centers, <u>EuroHealthNet</u>

#### Administrative support & coordination:

A IANPHI Secretariat staff member to provide administrative coordination support to the SC and relevant actors in charge of the project

Coordination, governance and human resources:



## Thank you for your attention!

5:35 – 6:30 pm	PHAC SESSION: BUILDING BRIDGES TO RESILIENCE – IDENTIFYING INTERNATIONAL GOOD-PRATICE PRINCIPLES IN APPLYING HEALTH PROMOTION TO EMERGENCY PREPAREDNESS AND RESPONSE During this session, the PHAC 2 project will be further discussed and IANPHI Members
	<ul> <li>Will be given the floor to share their ideas and contributions.</li> <li>The session will be moderated by Dr. Jean-Claude Desenclos, Scientific Advisor, Santé publique France (SpF), France, and Senior Executive Board Advisor for IANPHI</li> </ul>



Dr. George Leahy, Deputy Director Europe, & Dr. Carolina Arevalo Deputy

Dr. Carolina Arevalo, Deputy Director of Research, Evidence and Knowledge, UK Health Security Agency (UKHSA), United Kingdom England

# HOW THE UK WAS PREPARED TO CONDUCT REAL-TIME RESEARCH DURING THE PANDEMIC

INTRODUCTION



# The big questions



#### What are the research gaps?

Who identifies them? Who needs to know? How are they shared? What needs to be known NOW? What are the long-term questions? How do we manage changing landscape, evolution of unknowns? What evidence do we need? How do we find and synthesise evidence at pace? What is the best way to address them?

- Research
- Evaluation
- Surveillance

#### Who should do the research and how?

Who has capacity, capability, infrastructure, expertise? Where are the experts? How can we collaborate? What partnerships are in place? What does the public need/want? How to fund studies? What data do experts need to do research? What is in place now that can be stood up/pivoted? How can data access and approvals be streamlined?




# Pre-existing capacity and capability

203

**UK Health** 

Security

Agency









examples

Research partnerships and academic networks
 Research capacity and infrastructure
 Surveillance
 Sleeping studies and protocols
 Research funding mechanisms
 Rapid response funding calls (NIHR/UKRI)



## NIHR Health Protection Research Units



Partnerships between UKHSA (prev. PHE) and academia undertaking high quality research that aims to protect the public's health and minimise the health impact of emergencies.

Undertake research on predefined themes such as antimicrobial resistance, air pollution, radiation and
 chemical hazards, behavioural science, data and modelling, and infectious diseases.

Responsive research remit to support emerging UKHSA needs including from incidents.

During 2020, HPRUs undertook 48 COVID projects, leading to 56 papers and 2 letters to journals.

**COVID-19 household contact and transmission study:** ATACCC Study Investigators, Singanayagam, A, Hakki, S, Dunning, J, Madon, KJ, Crone, MA, Koycheva, A, Derqui-Fernandez, N, Barnett, JL, Whitfield, MG, Varro, R, Charlett, A, Kundu, R, Fenn, J, Cutajar, J, Quinn, V, Conibear, E, Barclay, W, Freemont, PS, Taylor, GP, Ahmad, S, Zambon, M, Ferguson, NM, Lalvani, A, Badhan, A, Dustan, S, Tejpal, C, Ketkar, AV, Narean, JS, Hammett, S, McDermott, E, Pillay, T, Houston, H, Luca, C, Samuel, J, Bremang, S, Evetts, S, Poh, J, Anderson, C, Jackson, D, Miah, S, Ellis, J & Lackenby, A 2022, 'Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study', *The Lancet Infectious Dise*, NP, P, 183-195. https://doi.org/10.1016/S1473-3099(21)00648-4





Easter Six Study Outbreak Investigation using serology to monitor COVID-19 in care home residents and staff



Six London care homes with COVID-19 outbreaks were investigated during the Easter weekend (EASTER6) and found high rates of infection with SARS-CoV-2 were found in residents and staff members. Many did not have any symptoms at the time. The investigation was continued through the measurement of antibodies against SARS-CoV-2 in residents and staff at the six care homes around one month after initial investigation

#### RESPOND

Ladhani, S, Chow, JY, Janarthanan, R, Fok, J, Crawley-Boevey, E, Vusirikala, A, Fernandez, E, Perez, MS, Tang, S, Dun-Campbell, K, Evans, EW, Bell, A, Patel, B, Amin-Chowdhury, Z, Aiano, F, Paranthaman, K, Ma, T, Saavedra-Campos, M, Myers, R, Ellis, J, Lackenby, A, Gopal, R, Patel, M, Brown, C, Chand-Kumar, M, Brown, K, Ramsay, M, Hopkins, S, Shetty, N & Zambon, M 2020, 'Investigation of SARS-CoV-2 outbreaks in six care homes in London, April 2020', *EClinicalMedicine*, vol. 26, 100533. https://doi.org/10.1016/j.eclinm.2020.100533







COVID-19 Rapid Survey of Adherence to Interventions and Responses

#### Stood up in 2020 to run for 2 years through the pandemic

- Based on 2012 sleeping study NIHR award to develop a set of questions to be used in the event of a future pandemic
- Focus on public attitudes, behaviours and impact of policies
- Recommendations provided to decision makers, policy makers and scientific advisory groups
- Collaboration between King's College London, University College London and Public Health England

#### PREPARE

Å

Rubin GJ, Bakhshi S, Amlöt R, Fear N, Potts HWW, Michie S. The design of a survey questionnaire to measure perceptions and behaviour during an influenza pandemic: the Flu TElephone Survey Template (FluTEST). Southampton (UK): NIHR Journals Library; 2014 Nov. PMID: 25642523.

#### RESPOND

Simpson, CR: Thomas, BD: Challen K: De Angelis, D: Fragaszy, E: Goodacre, S: Hayward, A: Lim, WS: Rubin, GJ; Semple, MG; Knight, M: 2020, 'The UK hibernated pandemic influenza research porfoilio: triggered for COVID-19, May 2020', The Lancet Infectious Diseases, vol. 20, Issue 7, P7670769 100533, https://doi.org/10.1016/S1473-3099(20)30398-4

#### INFORM

The COVID-19 Rapid Survey of Adherence to Interventions and Responses (CORSAIR) study: Final report. (Shared with DHSC, 22 June

- 2023 data reports
  - + 16 pre prints.
  - + 17 peer-reviewed publications

Simpson CR, Beever D, Challen K, De Angelis D, Fragaszy E, Goodacre S, Hayward A, Lim WS, Rubin GJ, Semple MG, Knight M; NIHR hibernated influenza studies collaborative group. The UK's pandemic influenza research portfolio: a model for future research on emerging infections. Lancet Infect Dis. 2019 Aug;19(8):e295-e300. doi: 10.1016/S1473-3099(18)30786-2. Epub 2019 Apr 18. PMID: 31006605.







### Rapid response funding and support UK Government funders



#### UK Research Institutes and National Institute for Health and Care Research (NIHR)

• Medical Research Council and NIHR rapid response funding calls

Providing vital research into COVID-19 immunity and vaccine

- Urgent Public Health Research prioritisation process for Clinical Research Network and NHS resources
- ISARIC Clinical Characterisation protocol
- National Core Studies
- Clinical trials for vaccine studies

UK Collaborative in Development Research Epidemics Funders group

- Coordination of funders
- Research tracker
- Living Mapping Review

Public Health England – UKHSA contributing through informing funders of emerging research priorities and undertaking research studies

#### di GOV.UK

Home > COVID-19

#### Guidance SIREN study

https://www.nihr.ac.uk

From: <u>UK Health Security Agency</u> Published 20 June 2022 Last updated 5 April 2024 — <u>See all updates</u>

effectiveness nationally.

The SARS-CoV-2 immunity and reinfection evaluation (SIREN) study is a unique, large-scale partnership with NHS healthcare workers providing an agile response to an evolving pandemic. It is one of the <u>national core studies</u> established in response to COVID-19 and a National Institute for Health Research (NIHR) urgent priority study, and continues to provide vital research into immunity and vaccine effectiveness.



https://ukcdr.org.uk/ce ebrating-covid-circle/




## Research and Science cell



The Research and Science cell was responsible for identifying and addressing major gaps in evidence to inform the COVID-19 response and coordination of the scientific activity of PHE/UKHSA


- Set up in February 2020 as part of the organisational incident response
- Membership across PHE/UKHSA experts, UK Devolved Administrators, Public
- Triaging research collaboration requests and assessment of requests of PHE data





#### Research and Science cell





distribution Sustainability of the NHS and social care Crime, policing and the criminal justice system

Diagnostics Collection of samples and data from people undergoing

sector • Ethical, Regulatory and Human Rights issues in responses to COVID-19 • Communication and Public Health during the pandemic treatment Serious mental health problems such as suicide, self-harm and eating disorders

**ANNUAL MEETING** 

APRIL 18-19, 2024 | BUDVA, MONTENEGRO

**IANPHI** 



#### Looking to the future



Identification of priority research questions for pandemic preparedness

> Informing research investment (HPRUs, sleeping studies, protocols)

Embedding research and evaluation into operational emergency response

Implementation of research prioritisation framework

Increasing evidence synthesis capacity

Increase evaluation capacity and embedding evaluation in research

International contribution

ANNUAL MEETING

APRIL 18-19, 2024 | BUDVA, MONTENEGRO



#### Looking to the future

Publishing UKHSA Science Strategy

Contribution to 100 Days Mission

Priority Pathogens List

Contribution to DHSC-led pandemic preparedness funders framework

Establishing Vaccines Development and Evaluation Centre and Diagnostics Accelerator

Agreed ethical review process of research studies involving UKHSA access to previously collected data (Health Research Authority)



203

UK Health Security

**UK Health** 

**UKHSA Science** 

Strategy 2023 to 2033 Securing health and

Security

Agency

# CLOSING REMARKS

THANK YOU!



Dr. Tyra Grove Krause, Executive Vice-President and Head of the Division of Epidemiological Infectious Diseases Preparedness, Statens Serum Institut (SSI), Denmark


# RESEARCH AS A CENTRAL PILLAR IN INFECTIOUS DISEASE PREPAREDNESS: THE EXPERIENCE OF SSI




## 120 years of experience



- Prevention and control of infectious diseases
  - Surveillance
  - Reference laboratory
  - Vaccine development
  - Vaccine supply
  - Scientific advice
  - Last 20 years build up a digital infrastructure for surveillance & research



DANMARKS NATIONALE **BIOBANK** 





Vision



Statens Serum Institut – An internationally leading research and preparedness organisation that strenghtens the health of humans and animals







#### Five strategic action areas

- Far-sighted and future-proof preparedness
- One Health
- Research and evidence as a foundation
- A strong data infrastructure
- Useful, open and transparent



### A long journey with many knowledge gaps

25.000 - Christmas/New·Jear	Vhole Genome Sequencing Vaccination roll-out VOC/V	Reopening Lifting almost all restrictions Mortality Admissions
ICU capacity Mortality	Rathematical modelling Omicron	
PPE Undetected cases Long Term Care Facilities Test Reopening Long COVID Mink Travel Children Test Mink	Schools Antigen test Automatic closures Reopening Corofet passport Reopening	A A A A A A A A A A A A A A A A A A A






## Public health surveillance



Ongoing systematic collection, analysis, interpretation and dissemination of health data used for public health prevention and practice



## Research based infectious disease preparedness






Research

Timely risk assessment and response








#### Public health research domains

STATENS



## National collaborations with academia





Whole genomic sequencing capacity



Seroprevalence studies





Syddansk Universitet

Evaluate testing efforts and contact tracing schemes



Phylodynamics /transmission patterns

#### Research collaboration with academia













#### Join forces in international research networks

• Nordic vaccine network supported by EMA

JAMA Cardiology | Original Investigation

#### SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents

Øystein Karlstad, MScPharm, PhD; Petteri Hovi, MD, PhD; Anders Husby, MD, PhD; Tommi Härkänen, PhD; Randi Marie Selmer, MSc, PhD; Nicklas Pihlström, MSc; Jørgen Vinsløv Hansen, MSc, PhD; Hanna Nohynek, MD, PhD; Nina Gunnes, MSc, PhD; Anders Sundström, BA, PhD; Jan Wohlfahrt, MSc, DMSC; Tuomo A. Nieminen, MSocSc; Maria Grünewald, MSc, PhD; Hanne Løvdal Gulseth, MD, PhD; Anders Hviid, MSc, DMSC; Rickard Ljung, MD, PhD, MPH





#### Join forces in international research networks



- Funded by EC and governed by HERA
- Sharing pathogens
- Complementing expertice

# DURABLE

Delivering a Unified Research Alliance of Biomedical and public health Laboratories against Epidemics



## Conclusion



- We need to fill out research competence gaps
- SSI works to strengthen research activities
  - Within our organisation
  - With academia nationally
  - International research networks
- Intervention studies !!!





Moderated by Elene Godziashvili, Head of CPD Division, National Center for Disease Control and Public Health, Georgia DISCUSSION: INCLUDING AN INTERVENTION ON RESEARCH COMPETENCE IN THE WORKFORCE STRATEGY